17754
document
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease . BACKGROUND Compliance studies have shown that patients with reflux symptoms generally take their medication only when experiencing these symptoms . AIM To evaluate the efficacy of on-demand rabeprazole maintenance therapy in patients with non-erosive reflux disease . METHODS This multicentre , randomized , double-blind , placebo-controlled , withdrawal study compared 6 months of on-demand treatment with rabeprazole 10 mg vs. placebo . Adults with a history of reflux symptoms , a negative endoscopy , and > or = 3 days of moderate to very severe heartburn in the 7 days before enrollment ( N = 535 ) entered 4 weeks of open-label , acute treatment with rabeprazole 10 mg once daily . Patients with complete symptom relief then entered the on-demand phase . The primary end-point was discontinuation due to lack of heartburn control during the on-demand phase . RESULTS Eighty-three percent ( 432 of 523 ) of patients reported complete symptom relief at the end of the acute phase . During on-demand treatment , rates of discontinuation because of inadequate heartburn control were 20 % ( 28 of 139 ) for placebo vs. 6 % ( 16 of 279 ) for rabeprazole ( P < 0.00001 ) . Antacid use was twofold higher in the placebo group vs. the rabeprazole group ( P = 0.0009 ) . CONCLUSIONS Rabeprazole 10 mg once daily is highly effective in acute symptom relief and as on-demand long-term maintenance therapy in non-erosive reflux disease patients .
17755
Intervention_Pharmacological
rabeprazole
17756
Intervention_Pharmacological
rabeprazole
17757
Intervention_Control
placebo-controlled
17758
Intervention_Pharmacological
rabeprazole
17759
Intervention_Control
placebo
17760
Intervention_Pharmacological
rabeprazole
17761
Intervention_Control
placebo
17762
Intervention_Pharmacological
rabeprazole
17763
Intervention_Control
placebo
17764
Intervention_Pharmacological
rabeprazole
17765
Intervention_Pharmacological
Rabeprazole
17766
Outcome_Physical
symptom relief
17767
Outcome_Physical
reflux disease
17768
Outcome_Other
efficacy
17769
Outcome_Physical
symptom relief
17770
Outcome_Other
discontinuation due to lack of heartburn control during the on-demand phase
17771
Outcome_Physical
symptom relief
17772
Outcome_Other
rates of discontinuation because of inadequate heartburn control
17773
Outcome_Other
Antacid use
17774
Outcome_Other
effective
17775
Outcome_Physical
acute symptom relief
17776
Participant_Condition
non-erosive reflux disease
17777
Participant_Condition
patients with reflux symptoms
17778
Participant_Condition
non-erosive reflux disease
17779
Participant_Age
Adults
17780
Participant_Condition
reflux
17781
Participant_Condition
heartburn
17782
Participant_Condition
non-erosive reflux disease